MRVI
Maravai LifeSciences Holdings, Inc.
Price Chart
Latest Quote
$5.64
+0.27 (+5.12%)
Current Price
| Previous Close | $5.37 |
| Open | $5.53 |
| Day High | $5.68 |
| Day Low | $5.46 |
| Volume | 1,048,085 |
Stock Information
| Shares Outstanding | 147.51M |
| Total Debt | $315.03M |
| Cash Equivalents | $165.92M |
| Revenue | $204.73M |
| Net Income | $-104.56M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.08B |
| EPS (TTM) | $-0.71 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.10B |
| Sales | $204.73M |
| Income | $-104.56M |
| Book/sh | $1.43 |
| Cash/sh | $1.12 |
| Employees | 416 |
Financial Ratios
| Quick Ratio | 4.68 |
| Current Ratio | 5.91 |
| Debt/Eq | 85.36 |
Returns & Margins
| ROA | -6.59% |
| ROE | -40.98% |
| Gross Margin | 30.12% |
| Operating Margin | 1.09% |
| Profit Margin | -51.07% |
Ownership
| Insider Ownership | 13.86% |
| Institutional Ownership | 88.43% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -60.71 |
| P/S | 10.17 |
| P/B | 3.94 |
Analyst Data
| Recommendation | none |
| Target Price | $5.70 |
Technical Indicators
| SMA20 | $5.02 |
| SMA50 | $4.37 |
| SMA200 | $3.56 |
| RSI | 79.06 |
| ATR | 0.2692 |
| Shares Float | 101.63M |
| Short Float | 6.34% |
| Short Ratio | 2.80 |
| Volatility | 0.71 |
| Rel Volume | 0.38 |
Performance History
| Week | +12.67% |
| Month | +28.30% |
| Quarter | +83.28% |
| 6 Months | +64.58% |
| YTD | +66.03% |
| Year | +167.54% |
| 3 Years | -59.03% |
| 5 Years | -87.31% |
| 10 Years | -81.09% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $5.64 | 1,048,085 |
| 2026-06-23 | $5.37 | 1,138,500 |
| 2026-06-22 | $5.25 | 1,468,500 |
| 2026-06-18 | $5.20 | 9,280,200 |
| 2026-06-17 | $5.22 | 1,920,400 |
| 2026-06-16 | $5.01 | 1,456,000 |
| 2026-06-15 | $4.96 | 2,916,000 |
| 2026-06-12 | $4.98 | 1,675,500 |
| 2026-06-11 | $5.21 | 2,740,800 |
| 2026-06-10 | $5.08 | 2,704,800 |
| 2026-06-09 | $5.10 | 3,115,300 |
| 2026-06-08 | $5.04 | 3,177,300 |
| 2026-06-05 | $5.02 | 2,270,100 |
| 2026-06-04 | $4.99 | 4,447,300 |
| 2026-06-03 | $4.84 | 4,934,000 |
| 2026-06-02 | $4.83 | 2,560,000 |
| 2026-06-01 | $4.75 | 2,052,400 |
| 2026-05-29 | $4.80 | 2,782,500 |
| 2026-05-28 | $4.64 | 2,104,300 |
| 2026-05-27 | $4.37 | 1,571,700 |
| 2026-05-26 | $4.38 | 5,118,400 |
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
đ° Latest News
This is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors Portfolio
Insider Monkey âĸ 2026-06-07T17:59:16Z
How The Maravai LifeSciences (MRVI) Narrative Is Shifting With New Targets And 2026 Guidance
Simply Wall St. âĸ 2026-05-15T01:29:19Z
Maravai (MRVI) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-09T20:35:31Z
Maravai LifeSciences Holdings, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-08T12:30:00Z
Maravai LifeSciences Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T09:09:48Z
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T21:55:06Z
All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy
Zacks âĸ 2026-05-06T16:00:02Z
Maravai LifeSciences (MRVI) Carrying Moderately Bullish Sentiment Despite Options-Linked Volatility
Insider Monkey âĸ 2026-04-14T05:59:32Z
How Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation Narrative
Simply Wall St. âĸ 2026-04-13T07:08:44Z
How The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value Targets
Simply Wall St. âĸ 2026-03-30T02:06:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $151,753,000 | $150,876,000 | $148,743,000 | $168,957,000 |
| Cost Of Revenue | $151,753,000 | $150,876,000 | $148,743,000 | $168,957,000 |
| Total Revenue | $185,743,000 | $259,185,000 | $288,945,000 | $883,001,000 |
| Operating Revenue | $185,743,000 | $259,185,000 | $288,945,000 | $883,001,000 |
| Expenses | ||||
| Interest Expense | $26,992,000 | $47,700,000 | $45,892,000 | $20,414,000 |
| Total Expenses | $314,273,000 | $331,868,000 | $317,413,000 | $316,585,000 |
| Other Income Expense | $-90,888,000 | $-168,502,000 | $664,369,000 | $3,132,000 |
| Other Non Operating Income Expenses | $-4,152,000 | $-2,381,000 | $667,549,000 | $-4,460,000 |
| Net Non Operating Interest Income Expense | $-15,556,000 | $-20,297,000 | $-18,165,000 | $-18,076,000 |
| Interest Expense Non Operating | $26,992,000 | $47,700,000 | $45,892,000 | $20,414,000 |
| Operating Expense | $162,520,000 | $180,992,000 | $168,670,000 | $147,628,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-130,773,000 | $-144,846,000 | $-119,029,000 | $220,205,000 |
| Net Interest Income | $-15,556,000 | $-20,297,000 | $-18,165,000 | $-18,076,000 |
| Interest Income | $11,436,000 | $27,403,000 | $27,727,000 | $2,338,000 |
| Normalized Income | $-45,598,248 | $20,112,153 | $-116,516,800 | $213,448,120 |
| Net Income From Continuing And Discontinued Operation | $-130,773,000 | $-144,846,000 | $-119,029,000 | $220,205,000 |
| Total Operating Income As Reported | $-215,266,000 | $-235,617,000 | $-31,648,000 | $574,216,000 |
| Net Income Common Stockholders | $-130,773,000 | $-144,846,000 | $-119,029,000 | $220,205,000 |
| Net Income | $-130,773,000 | $-144,846,000 | $-119,029,000 | $220,205,000 |
| Net Income Including Noncontrolling Interests | $-230,762,000 | $-259,622,000 | $-138,375,000 | $490,663,000 |
| Net Income Continuous Operations | $-230,762,000 | $-259,622,000 | $-138,375,000 | $490,663,000 |
| Pretax Income | $-234,974,000 | $-261,482,000 | $617,736,000 | $551,472,000 |
| Special Income Charges | $-86,736,000 | $-166,121,000 | $-3,180,000 | $7,592,000 |
| Interest Income Non Operating | $11,436,000 | $27,403,000 | $27,727,000 | $2,338,000 |
| Operating Income | $-128,530,000 | $-72,683,000 | $-28,468,000 | $566,416,000 |
| Gross Profit | $33,990,000 | $108,309,000 | $140,202,000 | $714,044,000 |
| Average Dilution Earnings | - | $0 | $0 | $206,071,000 |
| Per Share | ||||
| Diluted EPS | $-0.90 | $-1.05 | $-0.90 | $1.67 |
| Basic EPS | $-0.90 | $-1.05 | $-0.90 | $1.67 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,561,248 | $-1,162,847 | $-667,800 | $835,120 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-60,774,000 | $9,204,000 | $715,589,000 | $602,397,000 |
| Total Unusual Items | $-86,736,000 | $-166,121,000 | $-3,180,000 | $7,592,000 |
| Total Unusual Items Excluding Goodwill | $-86,736,000 | $-166,121,000 | $-3,180,000 | $7,592,000 |
| Reconciled Depreciation | $60,472,000 | $56,865,000 | $48,781,000 | $38,103,000 |
| EBITDA (Bullshit earnings) | $-147,510,000 | $-156,917,000 | $712,409,000 | $609,989,000 |
| EBIT | $-207,982,000 | $-213,782,000 | $663,628,000 | $571,886,000 |
| Diluted Average Shares | $144,360,000 | $137,906,000 | $131,919,000 | $255,323,000 |
| Basic Average Shares | $144,360,000 | $137,906,000 | $131,919,000 | $131,545,000 |
| Diluted NI Availto Com Stockholders | $-130,773,000 | $-144,846,000 | $-119,029,000 | $426,276,000 |
| Minority Interests | $99,989,000 | $114,776,000 | $19,346,000 | $-270,458,000 |
| Tax Provision | $-4,212,000 | $-1,860,000 | $756,111,000 | $60,809,000 |
| Impairment Of Capital Assets | $68,709,000 | $166,151,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $18,027,000 | $-3,217,000 | $3,180,000 | $-7,800,000 |
| Research And Development | $17,402,000 | $19,221,000 | $17,280,000 | $18,369,000 |
| Selling General And Administration | $145,118,000 | $161,771,000 | $151,390,000 | $129,259,000 |
| Other Special Charges | - | $3,187,000 | - | $208,000 |
| Gain On Sale Of Business | - | - | $0 | $0 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-68,593,000 | $-29,543,000 | $-130,263,000 | $17,634,000 |
| Total Assets | $770,577,000 | $1,008,244,000 | $1,487,450,000 | $2,282,315,000 |
| Total Non Current Assets | $474,326,000 | $579,098,000 | $787,538,000 | $1,434,413,000 |
| Other Non Current Assets | $2,615,000 | $7,238,000 | $17,876,000 | $24,440,000 |
| Goodwill And Other Intangible Assets | $280,972,000 | $354,835,000 | $547,016,000 | $527,584,000 |
| Other Intangible Assets | $151,543,000 | $194,957,000 | $220,987,000 | $243,916,000 |
| Current Assets | $296,251,000 | $429,146,000 | $699,912,000 | $847,902,000 |
| Other Current Assets | $13,368,000 | $18,145,000 | $18,948,000 | $25,798,000 |
| Inventory | $40,495,000 | $50,082,000 | $51,397,000 | $43,152,000 |
| Receivables | $25,498,000 | $38,520,000 | $54,605,000 | $146,814,000 |
| Accounts Receivable | $25,498,000 | $38,520,000 | $54,605,000 | $138,624,000 |
| Cash Cash Equivalents And Short Term Investments | $216,890,000 | $322,399,000 | $574,962,000 | $632,138,000 |
| Cash And Cash Equivalents | $216,890,000 | $322,399,000 | $574,962,000 | $632,138,000 |
| Cash Financial | $216,890,000 | $322,399,000 | $574,962,000 | $632,138,000 |
| Allowance For Doubtful Accounts Receivable | - | $-3,200,000 | $-1,400,000 | $-2,200,000 |
| Gross Accounts Receivable | - | $41,720,000 | $56,005,000 | $140,824,000 |
| Non Current Deferred Assets | - | - | $0 | $765,799,000 |
| Non Current Deferred Taxes Assets | - | - | $0 | $765,799,000 |
| Other Receivables | - | - | $1,118,000 | $8,190,000 |
| Non Current Prepaid Assets | - | - | - | $27,253,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $74,881,000 | - | - | - |
| Total Debt | $364,708,000 | $376,692,000 | $610,967,000 | $585,262,000 |
| Long Term Debt And Capital Lease Obligation | $350,507,000 | $362,979,000 | $598,114,000 | $573,553,000 |
| Long Term Debt | $286,331,000 | $290,492,000 | $518,707,000 | $521,997,000 |
| Current Debt And Capital Lease Obligation | $14,201,000 | $13,713,000 | $12,853,000 | $11,709,000 |
| Current Debt | $5,440,000 | $5,440,000 | $5,440,000 | $5,440,000 |
| Other Current Borrowings | $5,440,000 | $5,440,000 | $5,440,000 | $5,440,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $397,866,000 | $431,035,000 | $697,566,000 | $1,377,072,000 |
| Total Non Current Liabilities Net Minority Interest | $352,949,000 | $374,064,000 | $610,098,000 | $1,266,928,000 |
| Other Non Current Liabilities | $197,000 | $412,000 | $2,394,000 | $413,000 |
| Tradeand Other Payables Non Current | $0 | $4,082,000 | $6,388,000 | $7,682,000 |
| Non Current Deferred Liabilities | $2,245,000 | $11,000 | - | - |
| Non Current Deferred Taxes Liabilities | $2,245,000 | $11,000 | - | - |
| Current Liabilities | $44,917,000 | $56,971,000 | $87,468,000 | $110,144,000 |
| Other Current Liabilities | $1,893,000 | $1,543,000 | $3,024,000 | $10,000,000 |
| Current Deferred Liabilities | $2,987,000 | $3,285,000 | $5,516,000 | $4,753,000 |
| Payables And Accrued Expenses | $14,729,000 | $21,267,000 | $53,170,000 | $63,809,000 |
| Interest Payable | $4,043,000 | $4,566,000 | $9,202,000 | $7,700,000 |
| Payables | $3,652,000 | $12,736,000 | $18,799,000 | $49,274,000 |
| Total Tax Payable | $742,000 | $779,000 | $1,001,000 | $1,029,000 |
| Accounts Payable | $2,910,000 | $11,957,000 | $10,729,000 | $5,991,000 |
| Other Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $212,379,000 | $325,292,000 | $416,753,000 | $545,218,000 |
| Total Equity Gross Minority Interest | $372,711,000 | $577,209,000 | $789,884,000 | $905,243,000 |
| Stockholders Equity | $212,379,000 | $325,292,000 | $416,753,000 | $545,218,000 |
| Gains Losses Not Affecting Retained Earnings | $524,000 | $0 | - | - |
| Other Equity Adjustments | $524,000 | - | - | - |
| Retained Earnings | $10,118,000 | $140,891,000 | $285,737,000 | $404,766,000 |
| Other | ||||
| Ordinary Shares Number | $145,324,017 | $141,976,348 | $132,227,632 | $131,692,000 |
| Share Issued | $145,324,017 | $141,976,348 | $132,227,632 | $131,692,000 |
| Tangible Book Value | $-68,593,000 | $-29,543,000 | $-130,263,000 | $17,634,000 |
| Invested Capital | $504,150,000 | $621,224,000 | $940,900,000 | $1,072,655,000 |
| Working Capital | $251,334,000 | $372,175,000 | $612,444,000 | $737,758,000 |
| Capital Lease Obligations | $72,937,000 | $80,760,000 | $86,820,000 | $57,825,000 |
| Total Capitalization | $498,710,000 | $615,784,000 | $935,460,000 | $1,067,215,000 |
| Minority Interest | $160,332,000 | $251,917,000 | $373,131,000 | $360,025,000 |
| Additional Paid In Capital | $199,177,000 | $181,874,000 | $128,503,000 | $137,898,000 |
| Capital Stock | $2,560,000 | $2,527,000 | $2,513,000 | $2,554,000 |
| Common Stock | $2,560,000 | $2,527,000 | $2,513,000 | $2,554,000 |
| Non Current Accrued Expenses | $0 | $6,580,000 | $3,202,000 | $9,324,000 |
| Long Term Capital Lease Obligation | $64,176,000 | $72,487,000 | $79,407,000 | $51,556,000 |
| Current Deferred Revenue | $2,987,000 | $3,285,000 | $5,516,000 | $4,753,000 |
| Current Capital Lease Obligation | $8,761,000 | $8,273,000 | $7,413,000 | $6,269,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,107,000 | $17,163,000 | $12,905,000 | $19,873,000 |
| Current Accrued Expenses | $11,077,000 | $8,531,000 | $34,371,000 | $14,535,000 |
| Goodwill | $129,429,000 | $159,878,000 | $326,029,000 | $283,668,000 |
| Net PPE | $190,739,000 | $217,025,000 | $222,646,000 | $116,590,000 |
| Accumulated Depreciation | $-68,081,000 | $-52,708,000 | $-32,214,000 | $-19,502,000 |
| Gross PPE | $258,820,000 | $269,733,000 | $254,860,000 | $136,092,000 |
| Leases | $39,249,000 | $37,587,000 | $24,874,000 | $20,095,000 |
| Construction In Progress | $14,681,000 | $23,764,000 | $39,637,000 | $13,190,000 |
| Other Properties | $117,859,000 | $131,150,000 | $138,345,000 | $63,896,000 |
| Machinery Furniture Equipment | $87,031,000 | $77,232,000 | $52,004,000 | $38,911,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $18,571,000 | $23,058,000 | $19,379,000 | $7,716,000 |
| Work In Process | $7,318,000 | $10,050,000 | $12,680,000 | $21,950,000 |
| Raw Materials | $14,606,000 | $16,974,000 | $19,338,000 | $13,486,000 |
| Dueto Related Parties Current | - | $0 | $7,069,000 | $42,254,000 |
| Dueto Related Parties Non Current | - | - | $0 | $675,956,000 |
| Buildings And Improvements | - | - | - | - |
| Land And Improvements | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-70,722,000 | $-22,193,000 | $60,671,000 | $518,887,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-57,573,000 | $7,465,000 | $126,224,000 | $535,977,000 |
| Cash Flow From Continuing Operating Activities | $-57,573,000 | $7,465,000 | $126,224,000 | $535,977,000 |
| Operating Gains Losses | - | $3,187,000 | - | $208,000 |
| Investing Activities | ||||
| Capital Expenditure | $-13,149,000 | $-29,658,000 | $-65,553,000 | $-17,090,000 |
| Investing Cash Flow | $-31,405,000 | $-24,316,000 | $-122,310,000 | $-267,612,000 |
| Cash Flow From Continuing Investing Activities | $-31,405,000 | $-24,316,000 | $-122,310,000 | $-267,612,000 |
| Net Other Investing Changes | - | $-1,800,000 | - | $-13,278,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-16,499,000 | $-235,712,000 | $-61,090,000 | $-187,499,000 |
| Cash Flow From Continuing Financing Activities | $-16,499,000 | $-235,712,000 | $-61,090,000 | $-187,499,000 |
| Net Other Financing Charges | $-11,059,000 | $-1,319,000 | $-55,650,000 | $-184,417,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-5,440,000 | $-234,393,000 | $-5,440,000 | $-13,895,000 |
| Interest Paid Supplemental Data | $24,976,000 | $50,973,000 | $44,256,000 | $20,198,000 |
| End Cash Position | $216,890,000 | $322,399,000 | $574,962,000 | $632,138,000 |
| Beginning Cash Position | $322,399,000 | $574,962,000 | $632,138,000 | $551,272,000 |
| Effect Of Exchange Rate Changes | $-32,000 | $0 | $0 | $0 |
| Changes In Cash | $-105,477,000 | $-252,563,000 | $-57,176,000 | $80,866,000 |
| Net Issuance Payments Of Debt | $-5,440,000 | $-234,393,000 | $-5,440,000 | $-5,440,000 |
| Net Long Term Debt Issuance | $-5,440,000 | $-234,393,000 | $-5,440,000 | $-5,440,000 |
| Long Term Debt Payments | $-5,440,000 | $-234,393,000 | $-5,440,000 | $-13,895,000 |
| Net Business Purchase And Sale | $-18,990,000 | $0 | $-69,622,000 | $-238,349,000 |
| Purchase Of Business | $-18,990,000 | $0 | $-69,622,000 | $-238,969,000 |
| Net PPE Purchase And Sale | $-12,415,000 | $-22,516,000 | $-52,688,000 | $-15,985,000 |
| Sale Of PPE | $734,000 | $7,142,000 | $12,865,000 | $1,105,000 |
| Purchase Of PPE | $-13,149,000 | $-29,658,000 | $-65,553,000 | $-17,090,000 |
| Change In Working Capital | $-7,982,000 | $-12,614,000 | $97,844,000 | $-45,082,000 |
| Change In Other Current Liabilities | $-18,631,000 | $-6,299,000 | $-15,978,000 | $3,829,000 |
| Change In Other Current Assets | $181,000 | $153,000 | $861,000 | - |
| Change In Payables And Accrued Expense | $-11,973,000 | $-23,017,000 | $20,642,000 | $6,925,000 |
| Change In Accrued Expense | $-4,626,000 | $-23,740,000 | $15,358,000 | $8,503,000 |
| Change In Payable | $-7,347,000 | $723,000 | $5,284,000 | $-1,578,000 |
| Change In Account Payable | $-7,347,000 | $723,000 | $5,284,000 | $-1,578,000 |
| Change In Prepaid Assets | $1,626,000 | $1,813,000 | $7,275,000 | $-35,900,000 |
| Change In Inventory | $7,999,000 | $377,000 | $649,000 | $9,459,000 |
| Change In Receivables | $12,816,000 | $14,359,000 | $84,395,000 | $-22,272,000 |
| Changes In Account Receivables | $12,816,000 | $14,359,000 | $84,395,000 | $-22,272,000 |
| Other Non Cash Items | $1,866,000 | $1,766,000 | $-672,849,000 | $-9,252,000 |
| Stock Based Compensation | $30,174,000 | $49,415,000 | $34,588,000 | $18,670,000 |
| Asset Impairment Charge | $84,597,000 | $166,151,000 | $0 | $0 |
| Deferred Tax | $4,062,000 | $2,317,000 | $756,235,000 | $42,667,000 |
| Deferred Income Tax | $4,062,000 | $2,317,000 | $756,235,000 | $42,667,000 |
| Depreciation Amortization Depletion | $60,472,000 | $56,865,000 | $48,781,000 | $38,103,000 |
| Depreciation And Amortization | $60,472,000 | $56,865,000 | $48,781,000 | $38,103,000 |
| Amortization Cash Flow | $27,951,000 | $27,531,000 | $27,356,000 | $24,269,000 |
| Amortization Of Intangibles | $27,951,000 | $27,531,000 | $27,356,000 | $24,269,000 |
| Depreciation | $32,521,000 | $29,334,000 | $21,425,000 | $13,834,000 |
| Net Income From Continuing Operations | $-230,762,000 | $-259,622,000 | $-138,375,000 | $490,663,000 |
| Issuance Of Debt | - | $953,000 | $0 | $8,455,000 |
| Income Tax Paid Supplemental Data | - | $670,000 | - | $23,032,000 |
| Proceeds From Stock Option Exercised | - | $-2,082,000 | $-20,000 | $2,358,000 |
| Long Term Debt Issuance | - | $953,000 | $0 | $8,455,000 |
| Sale Of Business | - | $0 | $0 | $620,000 |
| Net Intangibles Purchase And Sale | - | $-1,500,000 | $0 | $0 |
| Purchase Of Intangibles | - | $-1,500,000 | $0 | $0 |
| Change In Other Working Capital | - | $-986,000 | $250,000 | $-7,123,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
| Common Stock Payments | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-06-20